海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Evaluation of 18F-FDHT PET/CT as an early treatment response marker in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.
- Castration-resistant prostate cancer;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Netherlands
- 2013-06-18
Authorised
- MISOBOLD - Prostate cancer hypoxia using BOLD MRI and 18F-FMISO PET imaging
- Prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- France
- 2017-07-12
Authorised
- A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER - THE JANUS TRIAL
- invasive prostate cancer br>MedDRA version: 12.1 Level: LLT Classification code 10036917 Term: Prostate cancer stage I
- Italy
- 2009-12-14
Authorised
- A PHASE II TRIAL TO ASSESS THE EFFICACY OF EFAVIRENZ IN METASTATIC PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE CANCER - FAVE
- Male patients aged 18 and over with castration-refractory metastatic prostate cancer histologically confirmed with WHO performance status ranged from 0 to 2, and without any clinical symptom related to disease progression. MedDRA version: 9.1 Level: LLT Classification code 10036947 Term: Prostatic cancer metastatic
- France
- 2008-06-19
Authorised
- A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
- Hormone-refractory prostate cancer MedDRA version: 9.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer
- Austria, Belgium, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Portugal, Spain, Sweden, United Kingdom
- 2007-11-20
Authorised
- RTaxot: Docetaxel-based concurrent chemo-hormono-radiation in high and very high-risk prostate cancer patients: a phase II multicenter trial - RTaxot
- high and very high-risk prostate cancer patients MedDRA version: 9.1 Level: LLT Classification code 10061183
- Italy
- 2010-04-26
Authorised
- Ensayo clínico fase IIIb, no aleatorizado, abierto, multicéntrico, de seguimiento de la seguridad de dosis mensuales de degarelix en pacientes con cáncer de próstata. A Phase 3b, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients with Prostate Cancer - FE200486CS34
- Cáncer de próstata MedDRA version: 9 Level: LLT Classification code 10060862 Term: Prostate cancer
- Finland, France, Italy, Portugal, Spain, Sweden
- 2009-03-09
Authorised
- SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer
- Metastatic, castration-resistant prostate cancer br>MedDRA version: 17.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- United Kingdom
- 2011-03-30
Authorised
- A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse - PEACE 2
- localized prostate cancer with high-risk features of relapse MedDRA version: 14.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- France, Germany, Italy, Spain, United Kingdom
- 2013-04-22
Authorised
- A pilot phase II study of digitoxin for Androgen-Independent Prostate Cancer (AIPC)
- Androgen-Independent Prostate Cancer
- Sweden
- 2006-11-09
